ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年04月28日 09時00分
Source:
Eisai
エーザイ、Institutional Investor誌の「The All-Japan Executive Team」において、「Most Honored Company」およびセクター第1位に選出
東京, 2020年04月28日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、米国金融情報誌「Institutional Investor」がこのたび発表した「The All-Japan Executive Team」のBiotechnology & Pharmaceuticalsセクターにおいて、「Best CEOs」「Best CFOs」でそれぞれ第1位となり、「Most Honored Company」およびセクター総合第1位に選定されたことをお知らせします。
本調査は、世界的に著名な金融情報誌である「Institutional Investor」が、世界の機関投資家やアナリストの投票をもとに優れたIR活動を行う日本企業をセクターごとに選出するランキングです。2020年は、189の機関に所属する約350名の投資家・アナリストが投票を行いました。当社は、投資家説明会をはじめとする高質なIR活動や、ESGへの積極的な取り組みなどが高い評価を受けるとともに、CEO内藤 晴夫が、信頼性、コミュニケーションの質、リーダーシップで高く評価されました。
詳細は、「Institutional Investor」誌ホームページをご参照ください。(英語)www.institutionalinvestor.com/research/9955/the-all-japan-executive-team
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念に定めています。当社は、この理念の実現のため、株主・投資家の皆様の権利を尊重し、経営の公正性・透明性を確保し、企業価値向上の一助となるIR活動に取り組んでまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202019.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi Advances Strategic Alliance with Google Cloud to Empower Frontline Workers with Field-Specific AI Agents
Oct 11, 2025 00:58 JST
Honda Issues Integrated Report - "Honda Report 2025"
Oct 11, 2025 00:46 JST
DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 11, 2025 00:21 JST
Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Oct 11, 2025 00:08 JST
MHIET and MHI-TC Complete Delivery of First "COORDY" Controller Providing Optimized Control of Multiple Power Sources
Oct 10, 2025 23:47 JST
Fujitsu migrates service operations virtualization platform used by 3,000 companies to Nutanix and introduces migration support services utilizing proven expertise
Oct 10, 2025 23:25 JST
Anime Tokyo Station: TV Anime 'SPYxFAMILY' Special Exhibition, New Designs Added for Admission Bonus Illustration Cards
Oct 10, 2025 11:30 JST
TANAKA to Provide Medals Expressing Every Runner's Trail through Flowing Curves for the Tokyo Legacy Half Marathon 2025
Oct 10, 2025 03:00 JST
Genequest and Fujitsu uncover new insights into genetics-lifestyle relationships through high-speed, reliable causal AI from Fujitsu Kozuchi
Oct 10, 2025 00:55 JST
Sharp Launches A3 MFPs (BP Series)
Oct 10, 2025 00:50 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Large Car Ferry HAMANASU
Oct 10, 2025 00:42 JST
Honda Celebrates 30th Anniversary of CR-V
Oct 09, 2025 23:54 JST
DASSAI MOON Project, the World's First Test Brewing of Sake in Space
Oct 09, 2025 23:23 JST
All-New Destinator Wins Gold Award at VMARK Vietnam Design Award 2025
Oct 09, 2025 22:17 JST
Mazda Tests Feasibility of Commercializing Corrosion Resistance Evaluation Service for Coated Components
Oct 09, 2025 21:29 JST
Sumitomo Metal Mining and Toyota Collaborate on Mass Production of Cathode Materials for All-Solid-State Batteries
Oct 09, 2025 20:40 JST
Fujitsu and ARYA develop high-precision AI solution for instant detection of suspicious behavior
Oct 08, 2025 14:39 JST
Toda, JTB and Fujitsu kick off NFT-powered digital transformation project to boost international tourism to Japan
Oct 08, 2025 13:39 JST
Fujitsu and Sony Bank partner to integrate generative AI into core banking system design and development
Oct 08, 2025 13:02 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Oct 08, 2025 12:03 JST
More Latest Release >>
Related Release
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
10/8/2025 12:03:00 PM JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
10/3/2025 6:01:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
9/29/2025 10:33:00 AM JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
9/24/2025 7:04:00 PM JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
9/17/2025 6:20:00 PM JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
9/12/2025 1:20:00 PM JST
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
9/8/2025 5:49:00 PM JST
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
9/4/2025 10:56:00 AM JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
9/3/2025 11:32:00 AM JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
9/1/2025 1:44:00 PM JST
More Press release >>